GLP-1 coverage in Alberta

Alberta's government-sponsored drug plans, administered through Alberta Blue Cross for eligible residents such as seniors, income-support recipients, and children in government care, can cover GLP-1 medications when they're prescribed for type 2 diabetes and approved under Special Authorization. Special Authorization means a prescriber has to submit clinical documentation showing the patient meets the plan's criteria before coverage is approved; it isn't automatic just because the drug appears on a formulary list.

Outside these government-sponsored groups, most working-age Albertans without an employer plan pay out of pocket or purchase individual private coverage, since Alberta does not run a universal, income-tested public drug plan comparable to some other provinces.

Special Authorization criteria for GLP-1s in Alberta are built around the diabetes indication, and no government-sponsored plan in the province extends that approval to weight-loss use. A prescription for Wegovy, Saxenda, or an off-label weight-loss use of a diabetes-indicated GLP-1 will not clear Special Authorization on weight-loss grounds alone.

This is consistent with the rest of the country: no provincial public drug plan currently reimburses a GLP-1 prescribed specifically for weight management. Special Authorization criteria are reviewed periodically, so if your clinical situation changes, it's worth asking your prescriber whether a new submission is warranted.

Given the limited reach of Alberta's government-sponsored drug plans among working-age adults, employer and private drug plans carry more weight here than in provinces with broader public coverage. Nationally, about 31% of employer plans now include some coverage for GLP-1s used for weight management, and Alberta's large base of employer-provided benefits, particularly in energy, professional services, and public sector employment, makes checking your specific plan worthwhile.

Plan terms vary: some require a body mass index threshold or prior authorization, some cap annual spending, and some exclude weight-loss indications while still covering the same medication for diabetes. Your plan booklet or benefits administrator is the most reliable source for your specific terms.

Albertans without applicable coverage for a GLP-1 prescription have had access to generic semaglutide at Costco Pharmacy for approximately $91/mo since the May 2026 launch of Canadian generics from Apotex and Dr. Reddy's; Costco's pharmacy does not require a paid membership.

Brand-name products remain considerably more expensive at retail pharmacies: Ozempic typically runs $250 to $310/mo, Wegovy $400 to $570/mo, Mounjaro $280 to $550/mo, and Zepbound $435 to $550/mo, before insurance or manufacturer savings programs are factored in.

If you're paying out of pocket in Alberta, ask your pharmacist or prescriber whether generic semaglutide is appropriate for your situation, since it prices well below brand Ozempic or Wegovy. If your prescription is for diabetes and you may qualify for a government-sponsored plan, confirm eligibility and make sure the Special Authorization paperwork is complete, since an incomplete submission is a common cause of an unexpectedly high pharmacy bill.

For brand products, manufacturer savings programs can help: Novo Nordisk's Ozempic savings card and WegovyCare, and Eli Lilly's myMounjaro (about $185/mo with eligible coverage) and LillyConnect (Zepbound copay as low as $25/mo), generally require existing private insurance to access their lowest tiers. Compounded GLP-1 products are not a legal option in Canada, including Alberta, and shouldn't be treated as a cost-saving alternative.